Option chain shows key data for Roadzen's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Roadzen.

Roadzen (NASDAQ:RDZN) Stock, Option Chain

Roadzen

Roadzen Inc is an insurance technology company on a mission to transform global auto insurance powered by advanced AI. Its clients comprise major insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.

Poor Investment Strategies

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

NANX

RDZN

System1 And 2 Other Stocks Under $2 Executives Are Buying

stock-1863880

Roadzen shares are trading lower by 9.5% Thursday afternoon. The company announced a plan to convert $3.5 million of short-term debt into Roadzen shares.

Why Roadzen (RDZN) Stock Is Trading Lower

Man.Markets.Shutterstock

Equities

Bonds

Specialty ETFs

Commodities

Economics

Federal Reserve

$BTC

SPDR Dow Jones Industrial Average ETF Trust

RDUS

TSLA

Select Sector SPDR-Consumer Discretionary

U.S. equities were little moved on Tuesday as investors continued to assess the potential for interest rate cuts following the latest economic data and comments from Fed Chair Jerome Powell.

Stocks Hold Steady As Powell Reassures On Disinflation Path, Warns About Debt Risks; Tesla Rallies, Job Openings Spike: What&#39;s Driving Markets Tuesday?

Roadzen Inc

Janney Montgomery Scott analyst Robert Farnam downgrades Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) from Buy to Neutral and announces $176 price target.

Downgrades

Price Target

Analyst Ratings

Janney Montgomery Scott Downgrades Hanover Insurance Gr to Neutral, Announces $176 Price Target

RBC Capital analyst Irene Nattel reiterates Metro (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MRU#TSX">MRU</a>) with a Sector Perform and maintains C$90 price target.

Reiteration

TSX:MRU

RBC Capital Reiterates Sector Perform on Metro, Maintains C$90 Price Target

WIIM

SRAD

Sportradar shares are trading higher after the company announced a multiyear agreement with MLB to provide sports performance analysis of prospects using its Synergy Coaching and Scouting solution.

Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) disclosed a contract from renewable energy company, RWE AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RWEOY#OTC">RWEOY</a>), to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42105671/rwe-to-harness-ai-driven-weather-modelling-with-hpe-private-cloud-ai" rel="noreferrer noopener">enhance weather data analysis</a>.
RWE has adopted HPE Private Cloud AI, part of the NVIDIA AI Computing by HPE portfolio, to streamline weather model data processing and enhance information retrieval with retrieval-augmented generation (RAG).
The on-premise solution allows RWE&#8217;s researchers to rapidly deploy private cloud AI infrastructure within policy frameworks, enabling quicker experimentation and scaling of AI projects across various domains and regions.
HPE Private Cloud AI, co-developed with NVIDIA and delivered via the HPE GreenLake cloud, offers RWE a streamlined platform for infrastructure management, process automation, and workload orchestration, including sustainability metrics.
This allows RWE&#8217;s research team to focus on model development, accelerating time-to-market and providing a competitive edge in the renewable energy sector.
Fidelma Russo, EVP &amp; GM, Hybrid Cloud &amp; CTO at HPE, said, &#8220;The ability to fine tune and inference AI-driven weather models will be a key enabler to unlock higher efficiencies for RWE&#8217;s renewable energy portfolio and will give them a significant competitive advantage in the market.&#8221;
&#8220;HPE Private Cloud AI is a unique turnkey solution that enables RWE&#8217;s researchers to reach the market quicker and handle massive datasets.&#8221;
Yesterday, Deloitte expanded its collaboration with HPE to implement the newly launched HPE Private Cloud AI with NVIDIA, enhancing its AI capabilities and accelerating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42085548/deloitte-and-hewlett-packard-enterprise-collaborate-to-deliver-private-cloud-ai-capabilities" rel="noreferrer noopener">deployment of Generative AI solutions</a>.
Investors can gain exposure to the stock via&nbsp;First Trust S&amp;P 500 Diversified Dividend Aristocrats ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNGZ#NASDAQ">KNGZ</a>) and Roundhill Generative AI &amp; Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHAT#NYSE">CHAT</a>).
Price Action: HPE shares are up 0.99% at $21.39 premarket at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42105704" target="_blank" rel="noreferrer noopener">SpaceX CEO Elon Musk Reveals Technical Glitch That Led Company To Drop Key Objective Of Starship&#8217;s 6th Test Flight</a></li>
</ul>

Large Cap

Contracts

CHAT

KNGZ

Rwe Ag Ord Bearer Dm5 American Depository Receipt

RWEOY

HPE Powers RWE's Renewable Energy with AI Weather Modeling

RBC Capital analyst Andrew Wong maintains NexGen Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NXE#TSX">NXE</a>) with a Outperform and raises the price target from C$10 to C$15.

TSX:NXE

RBC Capital Maintains Outperform on NexGen Energy, Raises Price Target to C$15

ROAD

Construction Partners shares are trading higher after the company raised its FY25 revenue guidance.

Addentax Group Corp. ("Addentax" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>), an integrated service provider focusing on garment manufacturing, logistics services, property management, and subleasing, has announced the signing of a Memorandum of Understanding (MOU) for nationwide strategic cooperation with Shenzhen Yingbin Brand Development Co., Ltd. ("Yingbin Brand"), a prominent brand management company headquartered in Guangdong.

ATXG

Addentax Group Corp. Announces Signing Of MOU For Strategic Cooperation With Shenzhen Yingbin Brand Development Co., Ltd., Offering A Wide Range Of Services In Brand Supply Chain Management, Product Supply Chain Solutions, And Marketing Supply Chain Strategies

Maximus shares are trading lower after the company on Wednesday reported worse-than-expected Q4 adjusted EPS results.

iQIYI shares are trading lower despite a Q3 earnings beat.

RBC Capital analyst Pammi Bir maintains Riocan REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/REI#TSX">REI</a>) with a Outperform and raises the price target from C$21 to C$22.

TSX:REI

TSX:REI/UN

RBC Capital Maintains Outperform on Riocan REIT, Raises Price Target to C$22

On Wednesday, Pyxis Oncology, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42099028/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical-phase-1-part-1-data" rel="noreferrer noopener">multiple solid tumors</a>.
Among evaluable Head and Neck Squamous Cell Carcinoma (HNSCC) patients treated at an identified dose range of PYX-201 from 3.6 – 5.4 mg/kg (n=6), a confirmed 50% objective response rate (ORR) was observed, including one confirmed complete response (CR) and two confirmed partial responses (PR).
The company additionally announced a Clinical Trial Collaboration Agreement with Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) for a Pyxis Oncology-sponsored study of PYX-201 in combination with Merck&#8217;s Keytruda (pembrolizumab) in patients with 1L and 2L HNSCC, HR+/HER2- breast cancer, and triple-negative breast cancer (TNBC) and sarcoma.
<ul>
<li>PYX-201 and Keytruda combination dose escalation and expansion study in 1L and 2L HNSCC with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the first half of 2026.</li>
</ul>
Exploratory PYX-201 Phase 1 monotherapy expansion cohorts are planned for ovarian cancer, NSCLC, HR+/HER2 breast cancer, TNBC, and sarcoma. Preliminary clinical data are expected in the second half of 2025.
<ul>
<li>The company also expects to initiate the PYX-201 and Keytruda combination study in HR+/HER2 breast cancer, TNBC, and sarcoma, with preliminary clinical data expected in the second half of 2025 and the first half of 2026.</li>
<li>Preclinical studies of PYX-201 combined with other agents in ovarian cancer and NSCLC will commence in 2025, followed by clinical studies with preliminary clinical data expected in 2026.</li>
</ul>
PYX-201 demonstrated favorable preliminary tolerability profile data with low incidence of dose discontinuation, interruptions, or delays due to treatment-related adverse events.
William Blair analysts note that PYX-201 shows limited effectiveness outside of head-and-neck cancer, with only 8.7% of patients (2 out of 23) responding to tolerable doses of 3.6 mg/kg, 4.4 mg/kg, and 5.4 mg/kg.
&#8220;At this point, we are unsure whether the three unconfirmed responses could ultimately be confirmed,&#8221; the analysts writes.
The analysts has reduced the probability of success for PYX-201 to 10% from 35%. The updated fair value stands at $250 million or roughly $4.25 per share, comprising $1.77 per share from PYX-201 and $2.48 per share of cash.
With no major stock-moving events expected until the second half of 2025, the analysts estimate the stock will trade around $2.80 per share soon. William Blair says it includes $1.77 per share for PYX-201 and $1.07 for remaining cash by late 2025.
William Blair downgrades <a target="_blank" href="https://www.benzinga.com/quote/PYXS/analyst-ratings" rel="noreferrer noopener">Pyxis to Market Perform</a>, saying, &#8220;Since we view the head-and-neck cancer results as difficult to differentiate, coupled with modest activity in other solid tumor histologies.&#8221;
Price Action: PYXS stock is down 42.15% to $2.21 during premarket trading on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42098028/qualcomms-shift-from-handsets-to-ai-and-automotive-wins-analysts-confidence" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s Shift From Handsets To AI And Automotive Wins Analysts&#8217; Confidence</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Biotech

Health Care

Movers

General

PYXS

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

SWVL

Swvl Signs Three-Year Contract With G4S In Saudi Arabia To Provide SaaS-Based Mobility Solutions, Enhancing Fleet Efficiency Across Riyadh, Jeddah, And Dammam With Over 14,000 Monthly Trips; Financial Terms Not Disclosed

NVDA

NVIDIA shares are trading higher following the company's Q3 earnings report.

Compass Point analyst Floris Van Dijkum upgrades Pebblebrook Hotel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) from Neutral to Buy and maintains the price target from $17 to $17.

Upgrades

Compass Point Upgrades Pebblebrook Hotel to Buy, Maintains Price Target to $17

RBC Capital analyst Pammi Bir maintains SmartCentres REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SRU#TSX">SRU</a>) with a Outperform and raises the price target from C$27 to C$28.

TSX:SRU

TSX:SRU/UN

RBC Capital Maintains Outperform on SmartCentres REIT, Raises Price Target to C$28

As of Nov. 21, 2024, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Natural Gas Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>)</h3>
<ul>
<li>On Nov. 14, Natural Gas Services posted better-than-expected quarterly earnings. &#8220;We delivered another quarter of significant top and bottom-line growth, as well as a material increase in net cash provided by operating activities, as we further grow and optimize our business,&#8221; said Justin Jacobs, Chief Executive Officer. &#8220;Compression demand, particularly in the Permian Basin, remains robust. We continue to capitalize on our favorable industry position, innovative compression units, and strong customer relationships to increase investments in our large horsepower fleet as we look to drive growth in rental fleet horsepower, rental revenue, and cash flow.&#8221; The company's stock gained around 32% over the past month and has a <a href="https://www.benzinga.com/quote/NGS">52-week high of $26.00</a>.</li>
<li>RSI Value: 81.77&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>NGS Price Action: Shares of Natural Gas Services closed at $25.91 on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Range Resources Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>)</h3>
<ul>
<li>On Oct. 22, the company posted better-than-expected quarterly earnings. Dennis Degner, the Company&#8217;s CEO, commented, &#8220;This month marks the 20th anniversary of Range drilling the first commercial Marcellus shale well. The Marcellus and Utica now produce nearly one-third of U.S. natural gas, and the U.S. has become the leading global supplier of safe, clean, affordable natural gas. We are tremendously proud of the role Range has played in this hugely impactful achievement and we are even more excited about what the future holds as global energy demand increases, improving the quality of life for billions of people living in energy poverty.&#8221; The company's stock gained around 17% over the past month and has a <a href="https://www.benzinga.com/quote/RRC">52-week high</a> of $39.33.</li>
<li>RSI Value: 76.05</li>
<li>RRC Price Action: Shares of Range Resources closed at $35.16 on Wednesday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42094434/top-3-consumer-stocks-that-are-ticking-portfolio-bombs">Top 3 Consumer Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Short Ideas

Top 2 Energy Stocks You May Want To Dump This Month

<ul>
<li>MSTR</li>
<li>NVDA</li>
<li>$BTC</li>
<li>CORN</li>
<li>MARA</li>
<li>COIN</li>
<li>SNOW</li>
<li>TSLA</li>
<li>AI</li>
<li>GLD</li>
</ul>
data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

COIN

CORN

MARA

MSTR

SNOW

Top 10 Trending Stocks On WallStreetBets As Of November 21, 2024 (Via Swaggy Stocks)

MULN

Mullen Automotive Prepares For Mid-2025 Launch Of US Battery Production, Expands Fullerton Facility With Additional High-Volume Battery Lines And Advanced R&D Capabilities To Support EV Innovation And Reduce Import Reliance

The 76,000-square-foot former Barnes &amp; Noble location has been empty for nearly two decades and is now under contract to Boston-based Hudson Group. According to the Boston Business Journal, citing sources familiar with the negotiations, the property is expected to sell for much less than its 2017 price tag of $63 million.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
Brown, who signed a record-breaking $303.7 million contract last year, planned to transform the five-story building into a hub for Black entrepreneurship. His vision included featuring Black-owned businesses on the street level and housing his startup accelerator program on the upper floors.
"A building is a core part of BostonXchange, so he's looking forward to finding a location," Malia Lazu, Brown's consultant on the initiative, told the Boston Business Journal. The search continues for an alternative site downtown or elsewhere in the city.
The report said that the NBA All-Star&#8217;s interest represents exactly what civic leaders hope to see for vacant downtown properties in post-pandemic Boston. Michael Nichols, president of the Downtown Boston Business Improvement District, supported Brown&#8217;s mission. &#8220;We remain motivated to work with Jaylen and his team to find a space that can serve as the long-term epicenter for their mission-focused work,&#8221; Nichols said.
Trending: Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a>
The property&#8217;s troubled history extends beyond the pandemic. After Barnes &amp; Noble closed in 2006, it sat vacant until L3 Capital and LaSalle Investment Management purchased it in 2017. Despite millions in upgrades, COVID-19 derailed their plans, forcing them to surrender the building to lender Wells Fargo last year to avoid foreclosure, the report noted.
Hudson Group, the prospective buyer, brings experience in transforming downtown Boston properties. The firm has converted buildings in the Leather District into residential units and partnered with Brookfield on a 26-story apartment tower on the Greenway.
Brown&#8217;s initiative, Boston XChange, launched this summer and recently announced its first cohort of 10 businesses. While the Washington Street location didn&#8217;t work out, his broader mission to address Boston&#8217;s racial wealth gap through real estate and entrepreneurship continues.
The setback points to the ongoing challenges in major commercial <a href="https://www.benzinga.com/real-estate/24/11/41702735/millionaire-in-10-years-these-real-estate-markets-might-take-you-there">real estate</a> markets. Property values have declined sharply since the pandemic, creating obstacles and opportunities for innovative development projects. 
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100. </a></li>
</ul>

Real Estate

Jaylen Brown Takes A Shot At Downtown Boston Real Estate, Misses 399 Washington

<a href="https://www.globenewswire.com/Tracker?data=7hELYvsZhYCPCZZRxPvWFPXftOcrsR529q0BccXuyCnKPo0Eoy124Va-2XR6jPg5lSEgNiJULTo2kF8gqq3OLW235gewhBmVmSataxtiQbM=">Lumos Pharma, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUMO#NASDAQ">LUMO</a>), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the <a href="https://www.globenewswire.com/Tracker?data=-kAJIm6iG1WBmRNwtlOVPPgHy3ST-VsJJJCqcM0zmevXz4rvwqE_vbVEwzbB0Yxipc_8dAs0TjYvUeSrDSvuIW1xcKSmhX2xa30Lg9ZcyZdvPQSiFvddVnL1YLSjeHDdRhQveDSqhDFvgWqa3NWE2rtGqKIhcfw1H6pT03o2laVM2Ak_lblI1TGslGc_Lhdu">62nd Annual European Society for Paediatric Endocrinology Meeting</a>, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK.

LUMO

Lumos Pharma Presents Updated Phase 2 OraGrowtH Data Demonstrating Sustained Growth On Oral LUM-201 To 24 Months In PGHD And Correlation Of Growth To LUM-201's Unique Pulsatile Mechanism Of Action At ESPE 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Roadzen (NASDAQ:<a href="https://investorplace.com/stock-quotes/rdzn-stock-quote/">RDZN</a>) just reported results for the first quarter of 2025.<ul><li>Roadzen reported earnings per share of -46 cents. This was below the analyst estimate for EPS of -35 cents.</li><li>The company reported revenue of $8.93 million.</li><li>This was 1.09% worse than the analyst estimate for revenue of $9.03 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/rdzn-stock-earnings-roadzen-for-q1-of-2025/">RDZN Stock Earnings: Roadzen Misses EPS, Misses Revenue for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

RDZN Stock Earnings: Roadzen Misses EPS, Misses Revenue for Q1 2025

Roadzen GAAP EPS of -$0.71 misses by $0.38, revenue of $8.9M misses by $3.74M

Roadzen Inc ( ($RDZN) ) has shared an update. Roadzen Inc. is set to revolutionize the global auto insurance industry with its AI-driven platform, ...

Roadzen Inc. Unveils AI-Driven Auto Insurance Innovations

Roadzen says its insiders and major shareholders extend lock-up agreements for another year

ThinkEquity initiated coverage of Roadzen (RDZN) with a Buy rating and $6 price target Roadzen is an "Insurtech company transforming global auto in...

Roadzen initiated with a Buy at ThinkEquity

17:27 EDT Roadzen (RDZN) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking f...

Roadzen files $100M mixed securities shelf

An announcement from Roadzen Inc ( ($RDZN) ) is now available. Roadzen Inc. has amended the vesting schedule for restricted stock units awarded to ...

Roadzen Inc Extends Vesting Schedule for Key Executives

Roadzen, Inc. Class A ( ($RDZN) ) has released its Q2 earnings. Here is a breakdown of the information Roadzen, Inc. Class A presented to its inves...

Roadzen Inc. Reports Strong Revenue Growth Amid Challenges

Roadzen GAAP EPS of -$0.32 misses by $0.24, revenue of $11.9M misses by $8.57M

Maxim analyst Allen Klee lowered the firm's price target on Roadzen (RDZN) to $4 from $7 but keeps a Buy rating on the shares. The company's Q3 rev...

Roadzen price target lowered to $4 from $7 at Maxim

Earnings

Press Releases

Roadzen Reports Record Revenue Growth in its First Fiscal Year as a Public Company

Roadzen CEO and Chairman Agree to Exchange $3.5 Million of Short-Term Debt for Equity in the Company

Financing

Roadzen Secures Mizuho Debt Extension and Facility Increase

Roadzen Named One of CNBC's World's Top InsurTech Companies for 2024

Roadzen Reports its Best Fiscal First Quarter Results in Q1 2025 Buoyed By Strong Year-Over-Year Revenue Growth and Addition of Several Marquee Clients

Roadzen to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024

Roadzen's Insiders and Major Shareholders Agree to Extend Lock-Up for an Additional Year

Roadzen to Present at the ThinkEquity Investor Conference October 30, 2024

Roadzen Unveils MixtapeAI: Next-Generation AI Agents for the Insurance Industry

Roadzen Reports Fiscal Second Quarter and First Half FY2025 Financial Results

ReAlpha Tech

XIAO-I Corporation - American Depositary Shares

XIAO-I

Argo Blockchain plc - American Depositary Shares

Argo Blockchain

Arqit Quantum

BIT Mining

BTCS

BTC Digital

Gorilla Technology Group Inc. - Ordinary shares

Gorilla Tech Gr

Gryphon Digital Mining, Inc - Common Stock

Gryphon Digital Mining

MicroCloud Hologram Inc. - Ordinary Shares

MicroCloud Hologram

Intellicheck

Issuer Direct

Aurora Mobile Limited - American Depositary Shares

Aurora Mobile

LivePerson

MMTEC

The9 Limited - American Depository Shares

The9

NiSun Intl Enterprise Development Group Co, Ltd - Class A Common Shares

NiSun Intl Enterprise Dev

OneConnect Financial Technology Co., Ltd. American Depositary Shares, each representing thirty ordinary shares

Comments

Roadzen

Roadzen (RDZN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga